Category REGENERATIVE MEDICINE

PIER MARIA FORNASARI
2026-01-25

ISSCR Develops Roadmap to Accelerate Pluripotent Stem Cell-Derived Therapies to Patients

“Charting the Translational Pathway: ISSCR Best Practices for the Development of PSC-Derived Therapies,” offers insights into the comprehensive, globally informed guide to navigating the complex journey from laboratory discovery to approved therapy. The International Society for Stem Cell Research (ISSCR) today announced the upcoming release of “Charting the Translational Pathway: ISSCR Best Practices for the

Read More

No Comments InCELL THERAPY
PIER MARIA FORNASARI
2025-12-26

A possible new treatment for impaired brain blood flow and related dementias is on the horizon.

Research by scientists at the University of Vermont Robert Larner, M.D. College of Medicine provides novel insights into the mechanisms that regulate brain blood flow and highlight a potential therapeutic strategy to correct vascular dysfunction. Their preclinical findings, published December 22 in Proceedings of the National Academy of Sciences, suggest that adding a missing phospholipid back into a

Read More

No Comments InAGEING RESEARCH
PIER MARIA FORNASARI
2025-12-26

Johns Hopkins Scientists Develop Targeted Therapy for T-Cell Lymphomas and Leukemias

Researchers at the Johns Hopkins Kimmel Cancer Center’s Ludwig Center developed a new treatment that selectively targets TRBC2-positive T-cell cancers, expanding a precision approach they established in 2024 for TRBC1-positive tumors. The therapy, an antibody-drug conjugate, targets a protein expressed on the surface of T-cell cancers to deliver a cancer cell-killing drug. The work, published Dec. 22 in Nature Cancer, provides

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2025-12-13

Roswell Park Study Shows IL-36 Gamma ‘Armored’ CAR T Cells Can Eradicate Solid Tumors

Team headed by Dr. Renier Brentjens finds reprogramming neutrophils is key to antitumor immune response  A laboratory study out of Roswell Park Comprehensive Cancer Center outlines a new way to boost the effectiveness of chimeric antigen receptor (CAR) T-cell therapy in solid-tumor cancers, resulting in their eradication. Led by Renier Brentjens, MD, PhD, Deputy Director and

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2025-12-12

Oregon Health Science University study: CAR-T therapy shows long-term survival for patients with lymphoma

Five-year data from clinical trial for adults with relapsed or refractory large B-cell lymphoma confirms lasting remissions in high-risk patients A study published in the Journal of Clinical Oncology confirms that one of the first Food and Drug Administration-approved CAR-T cell therapies offers long-term survival and potential cures for adult patients with relapsed or refractory large B-cell lymphoma, even

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2025-12-10

FDA Approves First Cellular Therapy to Treat Patients with Severe Aplastic Anemia

The U.S. Food and Drug Administration announced it has approved Omisirge (omidubicel-onlv), the first hematopoietic stem cell transplant (HSCT) therapy to treat patients with severe aplastic anemia (SAA). Omisirge is indicated for adults and pediatric patients 12 years and older with hematologic malignancies and now is approved for adults and pediatric patients six years and

Read More

No Comments InCELL THERAPY
PIER MARIA FORNASARI
2025-12-10

FDA and EMA Approve First Gene Therapy Treatment for Wiskott-Aldrich Syndrome to Fondazione Telethon ETS

Agency exercises regulatory flexibility to address unmet need for rare, life-threatening disease The U.S. Food and Drug Administration approved Waskyra (etuvetidigene autotemcel), the first cell-based gene therapy for the treatment of Wiskott-Aldrich syndrome (WAS). Waskyra is indicated for pediatric patients six months and older and adults with WAS who have a mutation in the WAS gene and

Read More

No Comments InGENE THERAPY RARE DISEASES
PIER MARIA FORNASARI
2025-12-07

Partial Match Parity: Increasing the Donor Pool for Hematopoietic Stem Cell Transplantation

Blood cancer patients who may have previously struggled to find a donor for transplantation now have more options. A new study shows that patients achieve good outcomes with an partial match drawn from the national public registry of donors when they are treated with the immune-suppressing drug cyclophosphamide. Survival rates at one year were on par

Read More

No Comments InCELL THERAPY